In newborns, macrophages perform a process called efferocytosis, which recognizes and eats dying cells. This process triggers the production of a bioactive lipid called thromboxane, signaling nearby ...

US-based pharmaceutical company Cumberland Pharmaceuticals has reported positive top-line outcomes from a Phase II trial of ifetroban as a potential treatment for Duchenne muscular dystrophy (DMD).

Subjects received either a daily dose of either 100mg (low dose) or 300mg (high dose) of the oral thromboxane receptor antagonist ifetroban or a placebo. Improvement in the heart’s left ventricular ...